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Objective: To examine 36-month effects of bilateral subthalamic stimulation (STN-DBS) on 
non-motor symptoms (NMS) compared to standard-of-care medical therapy (MED) in 
Parkinson’s disease (PD).  
Methods: Here we report the 36-month follow-up of a prospective, observational, controlled, 
international multicenter study of the NILS cohort. Assessments included NMSScale (NMSS), 
PDQuestionnaire-8 (PDQ-8), Scales for Outcomes in PD (SCOPA)-motor 
examination, -activities of daily living, and -complications, and levodopa equivalent daily dose 
(LEDD). Propensity score matching resulted in a pseudo-randomized sub-cohort balancing 
baseline demographic and clinical characteristics between the STN-DBS and MED group. 
Within-group longitudinal outcome changes were analyzed using Wilcoxon signed-rank and 
between-group differences of change scores with Mann-Whitney U test. Strength of clinical 
responses was quantified with Cohen’s effect size. Additionally, bivariate correlations of 
change scores were explored. 
Results: Propensity score matching applied on the cohort of 151 patients (STN-DBS n=67, 
MED n=84) resulted in a well-balanced sub-cohort including 38 patients per group. After 36 
months, STN-DBS significantly improved NMSS, PDQ-8, SCOPA-motor examination and  
–complications and reduced LEDD. Significant between-group differences, all favoring STN-
DBS, were found for NMSS, SCOPA-motor complications, LEDD (large effects), motor 
examination, and PDQ-8 (moderate effects). Furthermore, significant differences were found 
for the sleep/fatigue, urinary (large effects), and miscellaneous NMSS domains (moderate 
effects). NMSS total and PDQ-8 change scores correlated significantly. 
Conclusions: This study provides Class IIb evidence for beneficial effects of STN-DBS on 
NMS at 36-month follow-up which also correlated with quality of life improvements. This 




Deep brain stimulation (DBS) of the subthalamic nucleus (STN) improves quality of life (QoL), 
motor, and non-motor symptoms (NMS) in patients with Parkinson’s disease (PD).1-3 NMS are 
a key clinical aspect of PD and have been identified as the most important factor in determining 
QoL in patients with PD.4 Beneficial non-motor effects in patients undergoing STN-DBS have 
been observed in clinician-rated as well as laboratory-based investigations of a wide range of 
NMS, including polysomnography for sleep, urodynamic examinations for urinary symptoms, 
sniffing sticks for olfaction, as well as sensory signs such as thermal detection thresholds and 
pain thresholds.5 6 
Benefits of bilateral STN-DBS in patients with PD on a wide range of NMS have been reported 
for a follow-up period up to two years.3 It is unclear, if beneficial non-motor effects of STN-
DBS are sustained beyond 24 months. Non-motor effects of STN-DBS have been compared to 
apomorphine and levodopa infusion.7 However, little is known about the progression of non-
motor symptoms in patients undergoing standard-of-care medical treatment (MED). To our 
knowledge, a controlled study of non-motor effects of STN-DBS and MED has not been 
conducted yet. We hypothesized that beneficial motor and non-motor effects of STN-DBS can 
be observed in a controlled study at 36-month follow-up after surgery.  
2. METHODS 
2.1 Study design and ethical approval 
Here we report the 36-month follow-up of an ongoing, prospective, observational, controlled, 
international multicenter study (Class IIb evidence). Patients were recruited between 03/2011 
and 10/2015 as part of the DBS and medication arms of the NILS study7 which is a 
comprehensive study with non-motor profiling of PD as the primary outcome measure 
addressing the progression of NMS and treatment responses to medication and advanced 
  
 
treatments. Medical ethics committees of the participating centers approved the study protocol 
(master votes for Germany: Cologne, study number: 12-145, German Clinical Trials Register: 
DRKS00006735, and for the United Kingdom: National Research Ethics Service South East 
London REC 3, 10/H0808/141; NIHR portfolio, number: 10084). The study was carried out in 
accordance with the declaration of Helsinki. All patients gave written informed consent prior 
to any study procedures. 
2.2 Participants 
PD diagnosis was based on the UK Brain Bank criteria.8 As per clinical routine, patients in the 
DBS group were screened for DBS surgery according to the international guidelines, as 
described in previous publications by our group.7 9 Patients required a sufficient levodopa 
responsiveness (>30%) as assessed by the Unified PD Rating Scale-motor examination 
(UPDRS-III). Indications for DBS were based on multi-disciplinary assessments by movement 
disorders specialists, stereotactic neurosurgeons, neuropsychologists, psychiatrists, and when 
necessary, speech therapists and physiotherapists. Patients with clinically relevant psychiatric 
diseases or neuropsychological impairment (Mini-Mental State Examination scores<25) were 
excluded from this analysis. To ensure comparability between the STN-DBS and MED group, 
we included only patients in the MED group, who had advanced PD with dyskinesia, ON/OFF 
fluctuations or medication-refractory tremor. According to the multi-disciplinary assessments, 
patients in the MED group were considered candidates for STN-DBS but at that time preferred 
conservative non-surgical therapy according to published standard-of-care recommendations.10 
Patients’ informed decisions were shaped by a number of parameters, such as patients’ age, 
disease duration, dopaminergic medication requirements, and motor and non-motor symptom 
profiles. During the course of the study, patients in the MED group could undergo DBS at any 
time and patients in the DBS group could switch off neurostimulation at any time.  
  
 
2.3 Clinical assessment and outcome parameters 
Patients in both groups were assessed in the on-medication state (MedON) at baseline and 36-
month follow-up. The STN-DBS group was assessed in the medication and stimulation ON 
state (MedON/-StimON) at follow-up.  
The principal outcome measure was the Non-motor Symptom Scale (NMSS).11 The 30-item 
NMSS evaluates nine dimensions of NMS in PD: cardiovascular, sleep/fatigue, mood/apathy, 
perceptual problems/hallucinations, attention/memory, gastrointestinal symptoms, urinary 
symptoms, sexual function, and miscellaneous symptoms including items for pain, inability to 
smell/taste, weight change, and excessive sweating. The total score ranges from 0 (no 
impairment) to 360 (maximum impairment). 
Furthermore, assessments included the following secondary outcome measures: 
QoL was quantified by means of the PD Questionnaire (PDQ)-8, a short-form of the PDQ-3912 
covering eight dimensions contributing to QoL. The scale is recommended for QoL assessments 
by the Movement Disorders Society Scales Committee and has been commonly used in PD and 
in patients undergoing DBS.13 14 The PDQ-8 is reported as Summary Index (PDQ-8 SI) ranging 
from 0 (no impairment) to 100 (maximum impairment). 
The Scales for Outcomes in PD (SCOPA) was used to assess motor examination, activities of 
daily living, and motor complications. The scale is a well-established, validated short version 
of the Unified Parkinson’s Disease Rating Scale15, highly correlates with the corresponding 
UPDRS parts16 and its assessment time is approximately four time shorter than in the MDS-
Unified Parkinson’s disease rating scale.15 17 SCOPA subscales range from 0 (no impairment) 
to 42 (motor examination), 21 (activities of daily living), and 12 (motor complications).3 
The levodopa equivalent daily dose (LEDD) was computed according to the method by 
Tomlinson et al.18 
  
 
2.4 Statistical analysis 
Propensity score matching was used to create a pseudo-randomized19 sub-cohort balancing the 
following baseline demographic and disease parameters between the STN-DBS and MED 
group: age at baseline, disease duration since diagnosis, LEDD and SCOPA total score. The 
matching was conducted with Propensity Score Matching for SPSS (version 3.04)20 and SPSS 
25.0 (IBM Corporation). We implemented a 1:1 ratio nearest-neighbor matching algorithm with 
a 0.25 caliper without replacement and conducted balance diagnostics based on Cohen’s effect 
size |d|<0.25.21 
The assumption of normality was assessed with the Shapiro-Wilk test. Differences of baseline 
characteristics between the two treatment groups for dichotomous variables were analyzed 
using the Chi2-test and for continuous variables using Mann-Whitney U tests or unpaired t-
tests, when parametric criteria were fulfilled. To determine outcome changes from baseline to 
follow-up within each group, Wilcoxon signed-rank or paired samples t-tests were calculated. 
Mann-Whitney U tests of change scores between STN-DBS and MED groups (mean testbaseline 
− mean testfollow-up) were conducted to analyze differences of outcome parameter changes. 
Multiple comparisons resulting from the use of 7 scales were corrected with the Benjamini-
Hochberg procedure to account for multiple testing. All p values presented are two-sided and 
were adjusted to give a global family-wise significance threshold p<0.05. To determine clinical 
relevance of the responses, we calculated relative change [(𝑚𝑒𝑎𝑛 𝑡𝑒𝑠𝑡𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 −  𝑚𝑒𝑎𝑛 𝑡𝑒𝑠𝑡𝑓𝑜𝑙𝑙𝑜𝑤−𝑢𝑝 ) 
/𝑚𝑒𝑎𝑛 𝑡𝑒𝑠𝑡𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 ] and Cohen’s d effect size with a method by Morris for pretest-posttest-control 
group designs.22 Furthermore, the relationship between NMSS and PDQ-8 change scores was 
explored using Spearman correlation. 
3. RESULTS 
Of 317 patients screened, 151 were treated with STN-DBS or MED and met inclusion criteria 
(figure 1). Of 151 patients in the final sample (100 male) with a mean age of 63.8 ±9.8 years, 
  
 
67 patients underwent STN-DBS and 84 MED. The mean time to follow-up was 3.1 years. 
None of the patients in the MED group underwent STN-DBS during the 36-month follow-up 
period. 
3.1 Baseline characteristics in the original and matched cohort 
In the original cohort, patients in the STN-DBS group were significantly younger (61.3 ±8.5 
years vs. 65.8 ±10.4 years) with longer duration of PD (10.8 ±4.9 years vs. 7.5 ±5.0 years) and 
had greater dopaminergic medication requirements (LEDD 1199.1 ±587.5 mg/day vs. 778.1 
±407.1 mg/day) and more severe impairment in most of the clinical scales (table 1). 
Propensity score matching resulted in a sub-cohort of 76 patients (38 patients in each group). 
Balance diagnostics indicated a good matching between the two groups, i.e. no significant 
differences were found for the main demographic and clinical outcome parameters. Differences 
in NMSS domain scores were not significant except for sleep/fatigue. Baseline motor subscores 
and Mini-Mental State Examination scores of the matched cohort are available in the 
Supplementary table e-1.  
The results reported in this manuscript relate to the matched cohort. Additionally, outcome 
changes in the original cohort are reported in the Supplementary table e-2. 
3.2 Clinical Outcomes at Baseline and 36-month follow-up 
The time of follow-up assessment did not differ significantly between the groups (STN-
DBS=3.1 ±0.24 years, MED=3.1 ±0.47 years; p=0.580). Longitudinal within-group changes 
and between-group differences are reported in table 2. The STN-DBS group significantly 
improved in NMSS total score, PDQ-8 SI, SCOPA-motor examination, and -complications. No 
significant longitudinal change was found for SCOPA-activities of daily living. In the MED 
group, outcome parameters did not change significantly. As expected, LEDD was significantly 
reduced in the STN-DBS group, while it remained stable in the MED group. 
  
 
Post-hoc exploratory analyses of NMSS domains (see table 2 and figure 2) resulted in 
significant beneficial effects of STN-DBS for the sleep/fatigue, urinary, sexual function and 
miscellaneous domains. The latter was driven by pain (baseline, 2.2 ±3.3; follow-up, 0.6 ±1.5, 
p=0.008), inability to smell/taste (baseline, 3.5 ±4.0; follow-up, 1.6 ±3.2, p=0.008) and weight 
changes (baseline, 1.8 ±3.1; follow-up, 0.6 ±1.5, p=0.025). A significant worsening in the STN-
DBS group was found in the cardiovascular domain. In the MED group, the domains 
sleep/fatigue and urinary worsened significantly. 
Favoring STN-DBS, significant differences between change scores of STN-DBS and MED 
groups were found for the NMSS total score and the sleep/fatigue, urinary, and miscellaneous 
domains. The latter was driven by the inability to smell/taste and pain. Furthermore, favoring 
STN-DBS, significant differences were observed for PDQ-8 SI, LEDD, SCOPA-motor 
examination, and -complications. 
Table 3 shows change scores and relative changes from baseline to 36-month follow-up for 
both groups and Cohen’s d effect size for the differences in change scores between the two 
treatment groups. 
In the DBS group, we observed 6 Serious Adverse Events in 5 patients (skin perforation over 
battery site in two patients, disturbed wound healing, dopamine agonist withdrawal syndrome, 
suicide attempt, mania) which all resolved without major sequelae and 68 neurological Adverse 
Events in 40 patients and 25 psychiatric Adverse Events in 20 patients.  
3.3 Spearman correlation analyses 
There was a significant correlation of ‘moderate’ strength between change scores of NMSS 
total and PDQ-8 SI (see table 4). Explorative correlation analyses between change scores in 
NMSS domains and PDQ-8 SI revealed significant correlations for the domains sleep/fatigue 
(‘moderate’), mood/apathy, attention/memory, urinary, and miscellaneous (all ‘weak’). The 
  
 
correlation within the miscellaneous domain was driven by the inability to smell/taste  
(rs=0.354, p=0.002) and weight changes (rs=0.231, p=0.045). 
Additionally, Supplementary table e-3 reports Spearman correlations between change scores of 
PDQ-8 SI and NMSS for the separate treatment groups. In the STN-DBS and the MED group, 
LEDD was not correlated to PDQ-8 SI or NMSS (all p>0.05). There was a ‘weak’ correlation 
between change scores in PDQ-8 SI and SCOPA-motor examination ( rs =0.333, 




This study reports Class IIb evidence for beneficial effects of STN-DBS on a wide range of 
NMS in a controlled design at 36-month follow-up. Patients treated with STN-DBS experienced 
a better outcome of total NMS burden and specific non-motor aspects, such as sleep/fatigue, 
urinary symptoms, inability to smell/taste, and pain, than patients treated with MED. 
Motor symptoms, LEDD and (Serious) Adverse Events 
In line with previous studies, STN-DBS resulted in a significant improvement of motor aspects 
of PD.2 Confirming results from a study by Weaver et al., we observed an improvement of 
motor complications 36 months after STN-DBS.23 In accordance with this study, we observed 
a significant sustained 30% LEDD reduction at 36-month follow-up. In the MED group, 
standard-of-care practice10 stabilized motor examination, activities of daily living, and motor 
complications over the 36-month course of the study with no significant increase of 
dopaminergic medication. As expected, changes of medication requirements differed 
significantly between the two groups. Based on the sum of patient years, this result is well 





In line with a study by Holmberg et al. reporting no significant difference of cardiovascular 
outcomes between the STN-DBS and MED group at 12-month follow-up25, we observed no 
significant differences in the NMSS cardiovascular domain outcome at 36-month follow-up. 
However, when regarding longitudinal changes, we observed a significant worsening of 
cardiovascular symptoms in patients undergoing STN-DBS. The worsening of cardiovascular 
symptoms was unlikely to result from potential side effects of dopaminergic medication as these 
were significantly reduced postoperatively. In the STN-DBS group of the original cohort, 
cardiovascular symptoms at baseline were higher than in the matched sub-cohort and did not 
worsen at 36-month follow-up. Further studies are needed to investigate long-term effects of 
STN-DBS on cardiovascular symptoms in patients with high and low baseline cardiovascular 
impairments. 
This is the first controlled study reporting an improvement of subjective sleep/fatigue 
symptoms. Beneficial effects of STN-DBS on subjective sleep symptoms have been 
demonstrated in studies with follow-up periods up to three years.6 7 26 27 Our results are in line 
with a recent study by Choi et al. that found improvements in sleep dysfunction at three-year 
follow-up.26 Our study adds to the evidence on beneficial effects on quality of sleep by 
demonstrating improvements in a controlled design. In contrast, Lilleeng et al. reported no 
changes of sleep symptoms but a significant worsening of fatigue.28 However, this result was 
limited by the fact that the medication requirements at postoperative follow-ups remained high 
(LEDD at 1.0–1.5 years: 810 mg and at 6.0–9.0 years: 910 mg) and sleep and fatigue symptoms 
are common side effects of dopaminergic medication.29 As described in previous studies30 31, 
possible other mechanisms of STN-DBS effects on sleep/fatigue, besides LEDD reduction, are: 
a direct modulation of basal ganglia-thalamo-cortical loops resulting in improved nocturnal 




In accordance with previous evidence, we observed no significant changes of mood/apathy in 
the STN-DBS group at 36-month follow-up.23 However, this finding needs to be confirmed, as 
improved depression at 3-year follow-up after STN-DBS has been reported in Class IV 
evidence.32 Future studies addressing depression and its interplay with other neuropsychiatric 
symptoms, such as anxiety, hypomania, and alexithymia with longer follow-up are needed.33 
Perceptual problems/hallucinations remained unchanged from baseline to 36-month follow-up 
in the present study. In one of the few available studies on this issue, Yoshida et al. reported 
improved hallucinations in STN-DBS at 6-month follow-up.34 Future studies are needed to 
investigate the relationship of hallucination outcome and dopaminergic medication, 
psychotropic co-medication and the co-dependency with other neuropsychiatric aspects of PD. 
In our study, we observed no significant changes in attention/memory from baseline to 
36-month follow-up and no inter-group differences between STN-DBS and MED. This is in 
line with a study by Funkiewiez et al. that found no significant change of global cognitive 
functions and attention and memory subscales 3 years after surgery.32 This is also in line with 
a study by Zangaglia et al. with multiple follow-up visits up to 3 years which reported no 
significant worsening in memory tasks after STN-DBS, whereas verbal fluency performance 
deteriorated in the STN-DBS group and logical executive function tasks were only impaired 
transiently at 12-month follow-up. 35 
In our cohort we found no significant change of gastrointestinal symptoms at 36-month follow-
up. A study by Zibetti et al. reported a significantly lower prevalence of constipation at 24-
month follow-up.36 However, the authors did not employ validated scales and retrospectively 
extracted dichotomized data on the presence of constipation from patient charts. 
To our knowledge, this is the first study to report beneficial 36-month effects of STN-DBS on 
urinary symptoms compared to a MED control group. This is in line with previous studies with 
shorter follow-up periods.3 Herzog et al. reported ameliorations of bladder dysfunctions along 
with a modulation of blood flow of the posterior thalamus and the insular cortex.37 Nonetheless, 
  
 
long-term effects are unclear as Yamamoto et al. found no significant change in urodynamic 
parameters three years after surgery, which may have resulted from a relatively small sample 
size (n=13).38 
In the present study, sexual functions improved significantly in the STN-DBS group. This is in 
line with a study which reported an improvement of sexual function in 21 male patients 
undergoing STN-DBS in PD at a 9–12-month follow-up.39 In contrast, Kurcova et al. found no 
significant changes of sexual function in four female patients at a 4-month follow-up.40 
Therefore, the effect of STN-DBS on sexual function may depend on demographic parameters, 
such as sex of the patient. 
The present study shows beneficial effects on the miscellaneous domain. In our study, STN-
DBS significantly improved pain at 36-month follow-up and this beneficial effect was also 
significant in the between-group comparison. These results are consistent with previous reports 
of beneficial effects of STN-DBS on pain in a 1- to 8-year follow-up after surgery. 6 41 The 
mechanisms underlying the impact of STN-DBS on pain are not fully understood. Sensory 
gating has been discussed as a possible mechanism.31 To our knowledge, the present study is 
also the first to report beneficial effects of STN-DBS on subjective olfactory function at 36-
month follow-up. This is in line with studies showing beneficial immediate effects on odor 
identification6 and a PET study by Cury et al. provided evidence for an increased glucose 
metabolism in the midbrain and right frontal lobe in patients with improved olfactory function 
following STN-DBS.42 Our study extends the time frame of beneficial effects to 36 months 
after STN-DBS. We found no significant difference between the STN-DBS and the MED group 
for excessive sweating and for weight changes. In the literature, only few studies have reported 
significant changes of these non-motor aspects of PD in patients undergoing STN-DBS and for 
both symptoms the sample sizes of available studies were small and the follow-up periods 
short.6 A study by Petry-Schmelzer et al. provides a good overview of possible mechanisms of 
  
 
action (location-specific and general) which may mediate beneficial non-motor effects of STN-
DBS.31 
Quality of life 
Confirming the results of earlier studies, we observed a significant QoL improvement at 36-
month follow-up in the within-group analysis of the STN-DBS group.23 In the MED group, 
standard-of-care practice stabilized QoL over the 36-month course of the study. In line with 
previous studies with shorter follow-up periods up to two years,1 we observed a significantly 
greater QoL improvement after STN-DBS compared to MED at 36-month follow-up. QoL and 
NMS total burden correlated significantly in the overall matched cohort as well as in the STN-
DBS and MED groups separately. QoL correlated significantly with sleep/fatigue, 
mood/apathy, attention/memory, urinary, and the miscellaneous NMSS domains. QoL and 
motor examination were also significantly associated, but the correlation was weaker than with 
non-motor aspects, which is in line with previous studies and highlights the relative importance 
of NMS.43 QoL changes were significantly correlated to mood/apathy and attention/memory 
changes, indicating that although group level clinical effects per se were not significant, these 
non-motor outcomes were significantly related with postoperative QoL outcome on an 
individual level. 
Limitations 
There are several limitations in our study to be considered. While propensity score matching is 
a well-established tool to precisely match baseline characteristics between two groups, this 
method can only be applied to parameters assessed clinically. Therefore, this method does not 
consider potentially relevant parameters, which were not measured, for example impulse 
control disorders. To account for this limitation, comparisons between the matched groups in 
this study were only carried out conservatively using independent samples tests. Diagnostic 
statistics indicated a well-balanced matching for the selected matching parameters, and this also 
  
 
led to a good balance for most NMSS domains. A notable difference, however, was the mean 
NMSS sleep/fatigue domain, which was higher at baseline in the STN-DBS group than in the 
MED group and may have contributed to the greater improvement observed in the STN-DBS 
group. Conversely, we found low baseline impairment in the STN-DBS group, e.g., for the 
cardiovascular domain which may have left little room for additional improvements (floor 
effect). While propensity score matching can, therefore, not replace randomized controlled 
trials, it can increase causal inference in observational trials and is an important tool in situations 
in which the randomized controlled design may not be suitable (e.g. in the present study, 
investigations of long-term effects which would otherwise have resulted in withholding an 
effective therapy from severely affected patients for 3 years). In this context, one has to 
acknowledge, that one of the reasons why patients in the MED group might have decided 
against DBS therapy at that time, could have been their short disease duration (mean 7.5 years 
in the original cohort) which was even shorter than in the EARLYSTIM study (7.7 years).1 
Furthermore, in the STN-DBS group, the matching resulted in a selection of less severely 
affected patients with shorter mean disease duration, as there were too few matching partners 
from the MED group within the defined caliper. This is important, as the observed effects of 
STN-DBS may be different in patients with very severe PD. Further studies are required to 
investigate the dependence of STN-DBS outcomes on the levels of baseline impairments and 
predict long-term non-motor outcomes. We chose a conservative caliper (0.25) and conducted 
strict balance diagnostics21 to implement a precise matching between the two groups. A 
narrower caliper would have resulted in smaller matched cohort sizes. Nonetheless, to our 
knowledge, this cohort including 76 matched patients was one of the biggest in studies of its 
kind. The multicenter design of our study may reduce bias caused by single center studies and 
thus increase external validity. Another limitation was that the medication changes were not 
determined by an independent external panel as, e.g., in the EARLYSTIM study.1 However, 
the standard-of-care clinical procedures of movement disorder specialists in each center were 
  
 
based on the same criteria10 and clinical outcomes, such as PDQ-8 SI, SCOPA-motor 
examination, -activities of daily living, and -motor complications, and NMSS total burden did 
not worsen significantly in the MED group over the 36-month follow-up period, indicating a 
successful treatment of these aspects of PD. Furthermore, we analyzed Cohen’s d effect size to 
help the interpretation of our results with regard to the clinical relevance of the observed 
changes. However, the ideal method for this purpose would have been the use of minimal 
clinically important changes, which, to our knowledge, has not been published for the NMSS 
and its domains yet.  
 
Conclusion  
Our controlled study with a 36-month follow-up provides Class IIb evidence for a beneficial 
effect of STN-DBS on NMS total burden and a wide range of NMS, such as sleep/fatigue, 
urinary symptoms, pain, and olfactory functions. The clinical relevance of these non-motor 
outcomes is highlighted by their significant correlation with QoL improvements after STN-
DBS. Studies comparing QoL, motor and non-motor effects of different treatment options, e.g. 
for STN-DBS and standard-of-care medical therapy as investigated in this study, will help to 
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Original cohort (n=151)  Matched sub-cohort (n=76) 






n M SD  n M SD   n M SD n M SD   
Age 67 61.3 8.5  84 65.8 10.4  .003  38 62.0 8.9  38 62.5 11.5  .743 
Disease duration 67 10.8 4.9  84 7.5 5.0  <.001  38 9.9 4.2  38 8.7 5.3  .115 
Sex (female/male) [%] 67 25/42 [37.3/62.7]  84 26/58 [31/69]  .412  38 12/26 [31.6/68.4]  38 8/30 [21.1/78.9]  .297 
NMSS total score 67 60.6 36.0  83 46.0 25.3  .010  38 54.2 34.5  38 46.0 22.1  .436 
Cardiovascular 67 1.4 2.3  84 1.0 1.9  .549  38 0.8 1.3  38 1.3 2.3  .489 
Sleep/fatigue 67 14.7 10.1  84 9.2 8.6  <.001  38 13.0 9.1  38 7.4 6.9  .007 
Mood/ apathy 67 6.5 11.2  84 6.7 8.4  .215  38 6.3 12.1  38 7.4 8.3  .129 
Perceptual problems/ 
hallucinations 
67 1.2 3.1  84 1.1 2.3  .574  38 1.1 3.3  38 1.0 2.3  .621 
Attention/ memory 67 5.0 6.2  84 4.6 5.3  .668  38 5.5 5.6  38 5.3 5.1  .900 
Gastrointestinal 67 5.8 7.3  84 4.6 5.3  .615  38 4.4 5.5  38 4.9 5.7  .750 
Urinary 67 11.5 9.7  84 7.3 6.8  .018  38 10.6 9.8  38 6.5 6.3  .122 
Sexual function 67 3.4 5.2  84 4.2 5.8  .529  38 3.0 4.7  38 5.0 5.5  .085 
Miscellaneous 67 10.9 9.1  83 7.9 6.1  .078  38 9.2 8.7  38 7.3 5.5  .657 
PDQ-8 SI 67 32.8 18.5  84 26.2 15.4  .020  38 29.1 18.8  38 29.6 14.7  .495 
SCOPA-motor examination 67 11.6 5.2  84 10.1 4.6  .077  38 10.8 5.2  38 12.2 4.4  .147 
SCOPA-activities of daily living 67 6.9 3.4  84 6.4 3.0  .376  38 6.4 3.8  38 7.2 2.9  .224 
SCOPA-motor complications 67 4.8 3.1  84 3.1 1.7  <.001  38 3.6 3.0  38 3.4 2.0  .929 
LEDD 67 1199.1 587.5  84 778.1 407.1  <.001  38 1011.3 518.2  38 913.0 383.6  .540 
 
Legend: Demographic characteristics and outcome parameters at baseline in the original and matched cohorts. Significant results are highlighted in bold font. 
a Mann-Whitney U test or t test, when parametric test criteria were fulfilled.  
Abbreviations: LEDD = levodopa equivalent daily dose; MED = standard-of-care medical treatment; NMSS = Non-motor Symptom Scale; SCOPA = Scales 




Table 2 – Outcomes at baseline and 36-month follow-up in the matched cohort 
 
 
Legend: Outcome parameters at baseline and follow-up for the STN-DBS and MED groups. Multiple comparisons due to multiple outcome parameters were corrected with 
Benjamini-Hochberg’s method. Post-hoc exploratory analyses were performed for NMSS domains. Significant results are highlighted in bold font. 
Abbreviations: 36-MFU = 36-month follow-up; LEDD = levodopa equivalent daily dose; MED = standard-of-care medical treatment; NMSS = Non-motor Symptom Scale; PDQ-
8 SI = 8-item Parkinson’s Disease Questionnaire Summary Index; SCOPA = Scales for Outcomes in Parkinson’s disease; STN-DBS = subthalamic nucleus deep brain stimulation. 
a Wilcoxon signed rank test between baseline and 36-month follow-up to analyze within-group changes of outcome parameters 
b Mann-Whitney U test were used to analyze between-group differences of change scores between STN-DBS and MED group. 
 STN-DBS  MED 
  
 Baseline 36-MFU 
Baseline vs.  
36-MFU a 
  Baseline 36-MFU 




vs. MED b 
n M SD M SD p  n M SD M SD p  p 
NMSS total score 38 54.2 34.5 38.6 24.4 .018  38 46.0 22.1 62.8 40.0 .072  .003 
NMSS domains                
Cardiovascular 38 0.8 1.3 2.4 3.6 .012  38 1.3 2.3 1.5 2.8 .833  .117 
Sleep/fatigue 38 13.0 9.1 8.6 6.4 .003  38 7.4 6.9 12.5 8.8 .011  <.001 
Mood/apathy 38 6.3 12.1 4.2 6.9 .362  38 7.4 8.3 8.1 14.2 .585  .879 
Perceptual problems/ 
hallucinations 
38 1.1 3.3 1.0 2.0 .740  38 1.0 2.3 1.6 3.0 .160  .646 
Attention/memory 38 5.5 5.6 4.7 5.9 .530  38 5.3 5.1 7.2 8.0 .187  .242 
Gastrointestinal 38 4.4 5.5 5.1 4.9 .371  38 4.9 5.7 7.3 7.8 .062  .381 
Urinary 38 10.6 9.8 8.0 9.4 .037  38 6.5 6.3 12.0 10.4 .005  <.001 
Sexual function 38 3.0 4.7 1.0 2.7 .031  38 5.0 5.5 4.3 6.9 .475  .437 
Miscellaneous 38 9.2 8.7 3.7 4.5 <.001  38 7.3 5.5 8.3 8.8 .703  .007 
PDQ-8 SI 38 29.1 18.8 23.0 16.4 .024  38 29.6 14.7 35.8 18.2 .072  .004 
SCOPA-motor examination 38 10.8 5.2 8.1 5.0 .018  38 12.2 4.4 12.7 5.7 .507  .026 
SCOPA-activities of daily 
living 
38 6.4 3.8 5.8 3.5 .479  38 7.2 2.9 8.5 4.6 .131  .059 
SCOPA-motor complications 38 3.6 3.0 2.1 2.6 .018  38 3.4 2.0 4.1 2.4 .072  <.001 
LEDD (mg) 38 1011.3 518.2 703.9 504.2 .018  38 913.0 383.6 981.2 443.1 .550  .026 
  
 
Table 3 – Change scores, Relative changes and Effect sizes for matched cohorts 
 
 Change score  Relative change (%) 
 
Effect size 
 STN-DBS MED  STN-DBS MED  Cohen’s d Classification 
PDQ-8 SI 6.1 –6.2  21.0 –20.9   0.72 moderate 
SCOPA-motor examination 2.8 –0.5  25.7 –4.1   0.67 moderate 
SCOPA-activities of daily living 0.6 –1.3  9.4 –18.1   0.56 moderate 
SCOPA-motor complications 1.5 –0.7  63.9 –20.6   0.85 large 
LEDD 307.4 –68.2  30.4 –7.5   0.82 large 
NMSS total score 15.6 –16.8  28.8 –36.5   1.11 large 
Cardiovascular –1.6 –0.2  –200.0 –11.4   0.74 moderate 
Sleep/fatigue 4.4 –5.1  33.9 –67.8   1.16 large 
Mood/apathy 2.1 –0.7  33.3 –8.9   0.27 small 
Perceptual problems/ 
hallucinations 
0.1 –0.6  9.1 –61.0   0.24 small 
Attention/memory 0.8 –1.9  14.6 –35.0   0.50 moderate 
Gastrointestinal –0.7 –2.4  –15.9 –50.1   0.30 small 
Urinary 2.6 –5.5  24.5 –85.0   0.97 large 
Sexual function 2.0 0.6  66.7 12.3   0.25 small 
Miscellaneous 5.5 –1  59.8 –14.2   0.88 large 
 
Legend: Change scores and relative changes from baseline to 36-month follow-up in the STN-DBS and MED 
group. Effect sizes of the between-group comparison STN-DBS vs. MED (Mann-Whitney U test). 
 
Change score = (𝑚𝑒𝑎𝑛 𝑡𝑒𝑠𝑡𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 −  𝑚𝑒𝑎𝑛 𝑡𝑒𝑠𝑡𝑓𝑜𝑙𝑙𝑜𝑤−𝑢𝑝 ) 
Relative change = (𝑚𝑒𝑎𝑛 𝑡𝑒𝑠𝑡𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 −  𝑚𝑒𝑎𝑛 𝑡𝑒𝑠𝑡𝑓𝑜𝑙𝑙𝑜𝑤−𝑢𝑝 ) / 𝑚𝑒𝑎𝑛 𝑡𝑒𝑠𝑡𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 x 100.  
Cohen’s d = (mean pre-post changetreatment group –mean pre-post changecontrol group) / SD pretestpooled groups. 
Cohen’s d can be classified as ‘small’ (0.20≥d<0.50), ‘moderate’ (0.50≥d<0.80) and ‘large’ (d≥0.80). 
Effect size for the NMSS cardiovascular domain was favorable in the MED group and for all other outcome 
parameters and NMSS groups in the STN-DBS group.  
 
Abbreviations: LEDD = levodopa equivalent daily dose; MED = standard-of-care medical treatment; NMSS = 
Non-motor Symptom Scale; SCOPA = Scales for Outcomes in Parkinson’s disease; STN-DBS = subthalamic 




































rho .517*** .063 .523*** .256* .176 .274* .079 .334** .095 .377** 
p <.001 .59 <.001 .026 .129 .016 .497 .003 .413 .001 
n 76 76 76 76 76 76 76 76 76 76 
 
Legend: The relationship between change scores of PDQ-8 SI and NMSS (total and domain scores) was analyzed by Spearman 
correlations. Significant correlations are marked with stars.  
 
Correlation coefficients for significant results are highlighted in bold. 
* p < 0.050 
** p < 0.010 
*** p < 0.001 
Correlation coefficients were ‘weak’ (rho = 0.200 – 0.399) for mood/apathy, attention/memory, urinary symptoms, sexual functions, and 
miscellaneous domains, and ‘moderate’ (rho = 0.400 – 0.599) for the sleep/fatigue domain and the NMSS total score. 
 




Figure 1 – Patient selection 
 
 
Figure 2 – Non-motor Symptom Scale domains at baseline (blue) and 36-month 
follow-up (red) for the STN-DBS and MED groups in clustered boxplots (2a) and 
radar charts (2b)  
 
Legend: Figure 2 illustrates Non-motor Symptom Scale (NMSS) domains at baseline (blue) and 36-MFU 
(red) for the STN-DBS and MED groups in (A) clustered boxplots and (B) radar charts. Significant within-
group changes of NMSS domains from baseline to 36-MFU are highlighted with a black star and significant 
between-group differences (STN-DBS vs. MED) with a cross. (A) Outliers are illustrated with dots (2-3 
standard deviations) and extreme outliers with colored stars (>3 standard deviations). (B) NMSS domain 
scores are illustrated as percentage of maximum scores. Bigger areas represent more severe NMS 
impairment. 
In the STN-DBS group, NMSS sleep/fatigue, urinary, and miscellaneous domains significantly improved, 
and the cardiovascular domain significantly worsened from baseline to 36-MFU. In the MED group, NMSS 
sleep/fatigue and urinary domains significantly worsened from baseline to 36-MFU. Differences in NMSS 
domain scores were significant for sleep/fatigue, urinary, and miscellaneous domains. 
Abbreviations: 36-MFU = 36-month follow up; MED = standard-of-care medical treatment; STN-DBS = 
subthalamic nucleus deep brain stimulation 
